Elliott M. Antman

184.4k total citations · 32 hit papers
527 papers, 61.0k citations indexed

About

Elliott M. Antman is a scholar working on Cardiology and Cardiovascular Medicine, Surgery and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Elliott M. Antman has authored 527 papers receiving a total of 61.0k indexed citations (citations by other indexed papers that have themselves been cited), including 447 papers in Cardiology and Cardiovascular Medicine, 120 papers in Surgery and 110 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Elliott M. Antman's work include Acute Myocardial Infarction Research (235 papers), Atrial Fibrillation Management and Outcomes (153 papers) and Cardiac Imaging and Diagnostics (106 papers). Elliott M. Antman is often cited by papers focused on Acute Myocardial Infarction Research (235 papers), Atrial Fibrillation Management and Outcomes (153 papers) and Cardiac Imaging and Diagnostics (106 papers). Elliott M. Antman collaborates with scholars based in United States, Germany and Canada. Elliott M. Antman's co-authors include Eugene Braunwald, Carolyn H. McCabe, Sabina A. Murphy, Stephen D. Wiviott, Robert P. Giugliano, David A. Morrow, Eugene Braunwald, C. Michael Gibson, Christopher P. Cannon and Christian T. Ruff and has published in prestigious journals such as New England Journal of Medicine, The Lancet and JAMA.

In The Last Decade

Elliott M. Antman

514 papers receiving 58.1k citations

Hit Papers

Prasugrel versus Clopidog... 1990 2026 2002 2014 2007 2000 2013 2002 2008 1000 2.0k 3.0k 4.0k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Prasugrel versus Clopidogrel in Patients with Acute Coronary Syndromes
    2007 4.4k citations Stephen D. Wiviott, Eugene Braunwald et al. profile →
  2. Myocardial infarction redefined—a consensus document of The Joint European Society of Cardiology/American College of Cardiology committee for the redefinition of myocardial infarction
    2000 3.8k citations Elliott M. Antman et al. Journal of the American College of Cardiology profile →
  3. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials
    2013 3.3k citations Christian T. Ruff, Robert P. Giugliano et al. The Lancet profile →
  4. ACC/AHA 2002 Guideline Update for Exercise Testing: Summary Article
    2002 1.9k citations Elliott M. Antman, David P. Faxon et al. Circulation profile →
  5. Cytochrome P-450 Polymorphisms and Response to Clopidogrel
    2008 1.7k citations Jessica L. Mega, Stephen D. Wiviott et al. profile →
  6. ACC/AHA guidelines for the management of patients with acute myocardial infarction
    1996 1.4k citations Elliott M. Antman et al. Journal of the American College of Cardiology profile →
  7. ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non–ST-Elevation Myocardial Infarction
    2007 1.4k citations Elliott M. Antman et al. Circulation profile →
  8. Cardiac-Specific Troponin I Levels to Predict the Risk of Mortality in Patients with Acute Coronary Syndromes
    1996 1.3k citations Elliott M. Antman, Carolyn H. McCabe et al. profile →
  9. TIMI Risk Score for ST-Elevation Myocardial Infarction: A Convenient, Bedside, Clinical Score for Risk Assessment at Presentation
    2000 1.1k citations David A. Morrow, Elliott M. Antman et al. Circulation profile →
  10. Time Delay to Treatment and Mortality in Primary Angioplasty for Acute Myocardial Infarction
    2004 1.1k citations Elliott M. Antman et al. Circulation profile →
  11. ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices—Summary Article
    2002 916 citations Elliott M. Antman, David P. Faxon et al. Journal of the American College of Cardiology profile →
  12. ACC/AHA 2002 guideline update for exercise testing: summary article
    2002 879 citations Elliott M. Antman, David P. Faxon et al. Journal of the American College of Cardiology profile →
  13. Cumulative Meta-Analysis of Therapeutic Trials for Myocardial Infarction
    1992 836 citations Elliott M. Antman et al. profile →
  14. Enoxaparin Prevents Death and Cardiac Ischemic Events in Unstable Angina/Non–Q-Wave Myocardial Infarction
    1999 729 citations Elliott M. Antman, Carolyn H. McCabe et al. Circulation profile →
  15. 2012 ACCF/AHA Focused Update Incorporated Into the ACCF/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non–ST-Elevation Myocardial Infarction
    2013 704 citations Elliott M. Antman et al. Journal of the American College of Cardiology profile →
  16. Efficacy and safety of quinidine therapy for maintenance of sinus rhythm after cardioversion. A meta-analysis of randomized control trials.
    1990 703 citations Elliott M. Antman et al. Circulation profile →
  17. Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial
    2009 669 citations Gilles Montalescot, Stephen D. Wiviott et al. The Lancet profile →
  18. ACCF/ACG/AHA 2008 Expert Consensus Document on Reducing the Gastrointestinal Risks of Antiplatelet Therapy and NSAID Use
    2008 641 citations Deepak L. Bhatt, Elliott M. Antman et al. Circulation profile →
  19. Prasugrel Compared With High Loading- and Maintenance-Dose Clopidogrel in Patients With Planned Percutaneous Coronary Intervention
    2007 623 citations Stephen D. Wiviott, Andrew L. Frelinger et al. Circulation profile →
  20. 2007 Focused Update of the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction
    2008 619 citations Elliott M. Antman et al. Journal of the American College of Cardiology profile →
  21. ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices: Summary Article
    2002 616 citations Elliott M. Antman, David P. Faxon et al. Circulation profile →
  22. C-Reactive Protein Is a Potent Predictor of Mortality Independently of and in Combination With Troponin T in Acute Coronary Syndromes: A TIMI 11A Substudy
    1998 599 citations David A. Morrow, Elliott M. Antman et al. Journal of the American College of Cardiology profile →
  23. Use of Nonsteroidal Antiinflammatory Drugs
    2007 597 citations Elliott M. Antman et al. Circulation profile →
  24. Multimarker Approach to Risk Stratification in Non-ST Elevation Acute Coronary Syndromes
    2002 557 citations Marc S. Sabatine, David A. Morrow et al. Circulation profile →
  25. 1999 Update: ACC/AHA Guidelines for the Management of Patients With Acute Myocardial Infarction: Executive Summary and Recommendations
    1999 550 citations Elliott M. Antman et al. Circulation profile →
  26. Diabetes and Mortality Following Acute Coronary Syndromes
    2007 511 citations Carolyn H. McCabe, Sabina A. Murphy et al. profile →
  27. Full Coverage for Preventive Medications after Myocardial Infarction
    2011 508 citations Elliott M. Antman et al. profile →
  28. Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials
    2009 500 citations Michelle L. O’Donoghue, Elliott M. Antman et al. The Lancet profile →
  29. Greater Clinical Benefit of More Intensive Oral Antiplatelet Therapy With Prasugrel in Patients With Diabetes Mellitus in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel–Thrombolysis in Myocardial Infarction 38
    2008 498 citations Stephen D. Wiviott, Eugene Braunwald et al. Circulation profile →
  30. Cytochrome P450 Genetic Polymorphisms and the Response to Prasugrel
    2009 467 citations Jessica L. Mega, Stephen D. Wiviott et al. Circulation profile →
  31. Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON–TIMI 38 trial: a pharmacogenetic analysis
    2010 437 citations Jessica L. Mega, Stephen D. Wiviott et al. The Lancet profile →
  32. Association between edoxaban dose, concentration, anti-Factor Xa activity, and outcomes: an analysis of data from the randomised, double-blind ENGAGE AF-TIMI 48 trial
    2015 299 citations Christian T. Ruff, Robert P. Giugliano et al. The Lancet profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Elliott M. Antman United States 108 49.4k 17.3k 11.3k 9.6k 3.9k 527 61.0k
Keith A.A. Fox United Kingdom 109 47.7k 1.0× 15.5k 0.9× 11.2k 1.0× 12.1k 1.3× 4.8k 1.2× 834 59.8k
Harvey D. White New Zealand 99 45.2k 0.9× 21.6k 1.3× 14.0k 1.2× 5.8k 0.6× 3.8k 1.0× 719 57.9k
Eugene Braunwald United States 104 43.0k 0.9× 20.7k 1.2× 12.5k 1.1× 4.5k 0.5× 4.2k 1.1× 448 59.7k
Lars Wallentin Sweden 114 49.4k 1.0× 14.3k 0.8× 7.5k 0.7× 15.1k 1.6× 5.6k 1.4× 753 59.3k
Carolyn H. McCabe United States 80 29.7k 0.6× 17.3k 1.0× 9.7k 0.9× 5.1k 0.5× 3.0k 0.8× 182 38.6k
Christopher B. Granger United States 119 49.5k 1.0× 13.8k 0.8× 10.0k 0.9× 7.3k 0.8× 5.6k 1.4× 846 63.9k
Philippe Gabríel Steg France 123 56.5k 1.1× 30.1k 1.7× 10.3k 0.9× 9.6k 1.0× 5.6k 1.5× 1.1k 77.2k
Eugene Braunwald United States 127 50.8k 1.0× 30.6k 1.8× 12.1k 1.1× 8.0k 0.8× 6.7k 1.7× 703 77.3k
Sabina A. Murphy United States 97 30.0k 0.6× 17.9k 1.0× 6.4k 0.6× 5.8k 0.6× 3.3k 0.8× 487 43.5k
Bernard J. Gersh United States 138 61.8k 1.3× 19.2k 1.1× 13.7k 1.2× 5.1k 0.5× 7.2k 1.8× 1.1k 76.6k

Countries citing papers authored by Elliott M. Antman

Since Specialization
Citations

This map shows the geographic impact of Elliott M. Antman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Elliott M. Antman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Elliott M. Antman more than expected).

Fields of papers citing papers by Elliott M. Antman

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Elliott M. Antman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Elliott M. Antman. The network helps show where Elliott M. Antman may publish in the future.

Co-authorship network of co-authors of Elliott M. Antman

This figure shows the co-authorship network connecting the top 25 collaborators of Elliott M. Antman. A scholar is included among the top collaborators of Elliott M. Antman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Elliott M. Antman. Elliott M. Antman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Bergmark, Regan W., Sabina A. Murphy, Martin Unverdorben, et al.. (2025). Epistaxis Versus Nonepistaxis Bleeding in Anticoagulated Patients With Atrial Fibrillation: Results From the ENGAGE AF‐TIMI 48 Trial. Journal of the American Heart Association. 14(2). e031434–e031434.
2.
Zimerman, André, Frederick Kamanu, Giorgio Melloni, et al.. (2025). Polygenic risk score for coronary artery disease across the spectrum of atherosclerotic disease. European Journal of Preventive Cardiology.
3.
Haller, Paul M., Petr Jarolı́m, Andrea Bellavia, et al.. (2024). Heart Failure Risk Assessment Using Biomarkers in Patients With Atrial Fibrillation. Journal of the American College of Cardiology. 84(16). 1528–1540. 7 indexed citations
4.
Zimerman, André, Eugene Braunwald, Jan Steffel, et al.. (2024). Dose Reduction of Edoxaban in Patients 80 Years and Older With Atrial Fibrillation. JAMA Cardiology. 9(9). 817–817. 11 indexed citations
5.
Mills, Eric W., Michael Cassidy, Tamar Sofer, et al.. (2023). Evaluation of obstructive sleep apnea among consecutive patients with all patterns of atrial fibrillation using WatchPAT home sleep testing. American Heart Journal. 261. 95–103. 5 indexed citations
6.
Lau, Emily S., Eugene Braunwald, David A. Morrow, et al.. (2021). Sex, Permanent Drug Discontinuation, and Study Retention in Clinical Trials. Circulation. 143(7). 685–695. 20 indexed citations
7.
Groot, Joris R. de, Christian T. Ruff, Sabina A. Murphy, et al.. (2021). Edoxaban versus warfarin in patients with atrial fibrillation in relation to the risk of stroke: A secondary analysis of the ENGAGE AF-TIMI 48 study. American Heart Journal. 235. 132–139. 6 indexed citations
8.
Oyama, Kazuma, Robert P. Giugliano, David D. Berg, et al.. (2021). Serial assessment of biomarkers and the risk of stroke or systemic embolism and bleeding in patients with atrial fibrillation in the ENGAGE AF-TIMI 48 trial. European Heart Journal. 42(17). 1698–1706. 23 indexed citations
9.
Steffel, Jan, Robert P. Giugliano, Eugene Braunwald, et al.. (2015). Abstract 11748: Edoxaban versus Warfarin in Patients at Increased Risk of Falling - A Subgroup Analysis of the ENGAGE AF-TIMI 48 Trial. Circulation. 132(suppl_3). 4 indexed citations
10.
Frelinger, Andrew L., Alan D. Michelson, Eugene Braunwald, et al.. (2008). Abstract 3994: Pharmacodynamic Assessment of Platelet Inhibition by Prasugrel versus Clopidogrel in the TRITON-TIMI 38 Trial. Circulation. 118. 2 indexed citations
11.
Wiviott, Stephen D., Eugene Braunwald, Dominick J. Angiolillo, et al.. (2008). Greater Clinical Benefit of More Intensive Oral Antiplatelet Therapy With Prasugrel in Patients With Diabetes Mellitus in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel–Thrombolysis in Myocardial Infarction 38. Circulation. 118(16). 1626–1636. 498 indexed citations breakdown →
12.
13.
Murphy, Sabina A., et al.. (2007). Abstract 2221: Triple Therapy (TTx): ASA, Thienopyridine and Oral Anticoagulation (OA) Therapy Following ST Elevation Myocardial Infarction (STEMI): Is it Safe?. Circulation. 116. 2 indexed citations
14.
Wiviott, Stephen D., Eugene Braunwald, Carolyn H. McCabe, et al.. (2007). Prasugrel versus clopidogrel in patients with acute coronary syndromes: Commentary. Revista Portuguesa de Pneumologia. 26(11). 1297–1298. 2 indexed citations
15.
Mega, Jessica L., David A. Morrow, Erika Östör, et al.. (2007). Outcomes and Optimal Antithrombotic Therapy in Women Undergoing Fibrinolysis for ST-Elevation Myocardial Infarction. Circulation. 115(22). 2822–2828. 41 indexed citations
16.
Jacobs, Alice K., Elliott M. Antman, David P. Faxon, Tammy Gregory, & Penelope Solis. (2007). Development of Systems of Care for ST-Elevation Myocardial Infarction Patients. Circulation. 116(2). 217–230. 184 indexed citations
17.
18.
Kashani, Amir, C. Michael Gibson, Sabina A. Murphy, et al.. (2005). Angiography and revascularization in patients with heart failure following fibrinolytic therapy for ST-elevation acute myocardial infarction. The American Journal of Cardiology. 95(2). 228–233.
19.
Antman, Elliott M., et al.. (2000). Guidelines for the diagnosis and management of unstable angina and non-Q-wave myocardial infarction: Proposed revisions. American Heart Journal. 139(3). 461–475. 42 indexed citations
20.
Antman, Elliott M., Gitta Jacob, Bruce T. Volpe, Steven E. Finkel, & Michael R. Savona. (1978). Camphor overdosage. Therapeutic considerations.. Munich Personal RePEc Archive (Ludwig Maximilian University of Munich). 78(6). 896–7. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Keith A.A. Fox Breakdown of academic impact, for papers by Harvey D. White Breakdown of academic impact, for papers by Eugene Braunwald Breakdown of academic impact, for papers by Lars Wallentin Breakdown of academic impact, for papers by Carolyn H. McCabe Breakdown of academic impact, for papers by Christopher B. Granger Breakdown of academic impact, for papers by Philippe Gabríel Steg Breakdown of academic impact, for papers by Eugene Braunwald Breakdown of academic impact, for papers by Sabina A. Murphy Breakdown of academic impact, for papers by Bernard J. Gersh
Rankless by CCL
2026